Q3 2026 Orchid Pharma Ltd Earnings Call Transcript
Key Points
- Orchid Pharma Ltd (BOM:524372) has signed a binding term sheet in a key geography and a non-binding term sheet in a major regulated market, indicating progress in expanding its differentiated product portfolio.
- The company has increased its R&D investments to approximately 1.5% of sales, focusing on differentiated products and long-term competitiveness.
- Sales in Europe have commenced in Spain and Italy, with volumes increasing significantly, marking a more than 200% growth on a small base.
- The GCC region has seen launches in the United Arab Emirates and Kuwait, expanding the commercial presence of Orchid Pharma Ltd (BOM:524372) beyond Europe and India.
- The 7-ACA project is progressing as planned, with major equipment deliveries underway and mechanical completion targeted by September, which will enhance backward integration and cost competitiveness.
- Orchid Pharma Ltd (BOM:524372) reported a 5% decline in sales for Q3 compared to the previous year, and a 16% decline on a nine-month basis.
- EBITDA margins have significantly decreased from 17% last year to 6% this quarter, reflecting ongoing pricing pressures in the global antibiotics market.
- The oral segment has experienced approximately 12% price erosion and 10% quantity erosion over nine months, indicating broad industry pressure.
- The company's regulated market sales have decreased, with the mix shifting from 1/3 to 1/4, highlighting challenges in these markets.
- Gross margins have been pressured due to price-sensitive spot-based business and inventory devaluation, with current gross margins at 31% compared to historical levels.
Ladies and gentlemen, good day and welcome to the Orchid Pharma Limited Q3 FY26 earnings conference call hosted by Systematix Shares and Stocks Limited. (Operator Instructions) Please note that this conference has been recorded. I now hand the conference over to Mr. Vishal Manchanda from Systematix Shares and Stocks. Thank you and over to you, sir.
()-
Thank you, Anushka. Good evening, everyone. On behalf of Systematix Institutional Equities, I welcome you to the Q3 FY26 earning call of Orchid Pharma. We thank the Orchid Pharma management for giving us an opportunity to host the call.
Today we have with us the senior management of the company represented by Mr. Manish Dhanuka, Managing Director, Mr. Mridul Dhanuka, Whole-Time Director, Mr. Sunil Kumar Gupta, Chief Financial Officer, and Mr. Kapil Dayya, Company secretary. I now hand over the call to the company management. Over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
